Standing Committee on the Law of Patents

Twenty-Seventh Session
Geneva, December 11 to 15, 2017

DRAFT REFERENCE DOCUMENT ON EXCEPTION REGARDING ACTS FOR OBTAINING REGULATORY APPROVAL FROM AUTHORITIES

Document prepared by the Secretariat

INTRODUCTION

1. At its twenty-sixth session, held in Geneva from July 3 to 6, 2017, the Standing Committee on the Law of Patents (SCP) agreed that the Secretariat would prepare a draft reference document on exceptions and limitations to patent rights in conjunction with patent protection, which would contain the following elements for each exception and limitation: (i) the description of the exception and limitation; (ii) its objectives and goals; (iii) national/regional implementation; (iv) challenges faced by Member States in its implementation; and (v) results of its implementation. It was also agreed that, as a first step, the draft reference document to be submitted to the twenty-seventh session of the SCP would cover the exception regarding acts for obtaining regulatory approval from authorities. In addition, it was agreed that the Secretariat would invite Member States to send any additional inputs for the preparation of the draft reference document and make use of all information available from the SCP activities (see document SCP/26/7, paragraph 19, third bullet point, under “Exceptions and Limitations to Patent Rights”).

2. Pursuant to the above decision, the Secretariat invited Member States and Regional Patent Offices, through Note C. 8887, dated August 21, 2017, to submit to the International Bureau any additional inputs for the preparation of the draft reference document on exception regarding acts for obtaining regulatory approval from authorities (hereafter “regulatory review exception”).
3. Accordingly, Annex to this document contains the said draft reference document for the Committee’s discussions at its twenty-seventh session to be held in Geneva from December 11 to 15, 2017. As mandated by the Committee, the primary source of information for the preparation of the reference document was information collected through the SCP activities. Since 2009, a substantive amount of information has been collected on the subject of exceptions and limitation to patent rights. In preparation of this document, the Secretariat consulted and made use of, among others: (i) Reports of the various SCP sessions; (ii) Responses to the Questionnaire on Exceptions and Limitations to Patent Rights, submitted by the Member States and regional patent offices; (iii) Seminar on the Relationship between Patent Systems and the Availability of Medicines in Developing Countries and Least Developed Countries (SCP/23); (iv) Sharing Session on Countries’ Use of Health-Related Patent Flexibilities (SCP/20); (v) Experts’ Study on Exclusions from Patentable Subject Matter and Exceptions and Limitations to the Rights (SCP/15/3); (vi) SCP documents produced by the Secretariat, including Preliminary Study on the Issue of Exclusions from Patentable Subject Matter and Exceptions and Limitations to the Rights (SCP/13/3), Exceptions and Limitations to Patent Rights: Acts for Obtaining Regulatory Approval from Authorities (SCP/21/3) and Practical Experiences on the Effectiveness of, and Challenges Associated to, Exceptions and Limitations (SCP/25/3).

4. In addition, pursuant to the decision made at the twenty-sixth session of the SCP, the Secretariat made use of additional inputs provided by the Member States and the regional patent offices during the intersessional period between the twenty-sixth session and the twenty-seventh session of the SCP, which are available on the website of the SCP electronic forum at: http://www.wipo.int/scp/en/meetings/session_27/comments_received.html. Further, reflecting the discussions at the twenty-sixth session of the SCP, the Secretariat also consulted other sources in order to obtain supplementary information.

5. The reference document contains the following sections: (i) description of the regulatory review exception; (ii) objectives and goals; (iii) the multilateral legal framework of the regulatory review exception; (iv) national/regional implementation; (v) challenges faced by Member States in implementing the exception; and (vi) results of the national/regional implementation. In addition, it contains an Appendix, in which national legal provisions on the regulatory review exception are compiled. The Appendix updates and supplements the information contained in a similar compilation found in document CDIP/5/4, Annex I.

6. Since it is a first draft of the reference document with respect to the regulatory review exception, the final layout and presentation of the information concerned will be dealt at a later stage. Nevertheless, text boxes are introduced in the document in order to improve the readability of the reference document.

[Annex follows]
DRAFT REFERENCE DOCUMENT ON EXCEPTION REGARDING ACTS FOR OBTAINING REGULATORY APPROVAL FROM AUTHORITIES
# TABLE OF CONTENTS

- DESCRIPTION OF THE EXCEPTION ................................................................. 3
- OBJECTIVES AND GOALS ............................................................................. 4
- THE REGULATORY REVIEW EXCEPTION AND MULTILATERAL AGREEMENTS .... 5
- NATIONAL AND REGIONAL IMPLEMENTATION ............................................. 7
  - General experimental/scientific research exception or specific regulatory review exception ................................................................. 7
  - Who is entitled to use the exception? .......................................................... 8
  - Products covered ....................................................................................... 10
  - Permitted acts .......................................................................................... 12
  - Act carried out to obtain regulatory approval in other countries .................. 14
  - Time to file a regulatory review request .................................................... 15
  - Conditions for the exception to be applied ............................................... 16
- CHALLENGES FACED BY MEMBER STATES IN IMPLEMENTATING THE EXCEPTION ................................................................. 16
- RESULTS OF THE NATIONAL/REGIONAL IMPLEMENTATION ....................... 17

APPENDIX
DESCRIPTION OF THE REGULATORY REVIEW EXCEPTION

1. Some products, typically pharmaceutical products, cannot be marketed without obtaining marketing approval from a competent regulatory authority. Requirements for obtaining such marketing approval differ from one country to another, or from one sector to another, or even within the same sector, depending on many factors. For example, the authorization for new chemical entities is much more complex than the authorization for an “equivalent” one for which abbreviated, simplified procedures are applied. In general, in order to obtain a marketing authorization, an applicant is required to submit certain amount of information on the product that typically requires the production and testing of its samples. Such production and use of the product for testing may be considered an infringement of the patent, if the applicant is not the patentee.

2. Regulatory approval may take several years. If a third party cannot use the patented invention in order to obtain such regulatory approval prior to the expiration of the patent, market entry of competitive products, such as generics and biosimilars, would be delayed. To mitigate this situation, many patent laws provide for the regulatory review exception which, in general, entitles a third party to use a patented invention, without the consent of the patent holder, before the end of the patent protection, if such use is for the purposes of developing information to obtain a marketing approval.

3. The list of products that require regulatory approval for putting them on the market varies from country to country. While pharmaceutical sector remains highly regulated in many countries, and therefore subject to the exception in many of those countries, this phenomenon is not unique in this sector. Other sectors like plant protection products, herbicides and pesticides, animal feeding stuffs, flavoring substances and medical equipment are also highly regulated. Thus, in some countries, the regulatory review exception covers those products as well.

Box 1. “Bolar” Exception in the United States of America

The regulatory review exception is also known as the “Bolar exception”, after a well-known 1984 case in the United States of America, Roche Products v Bolar Pharmaceuticals. The Court of Appeals for the Federal Circuit ruled that the experimental use exception in the United States of America did not cover Bolar’s acts to carry out equivalency tests for the regulatory approval of generic medicines before the expiration of the relevant patent owned by Roche. The court held that “Bolar’s intended “experimental” use is solely for business reasons and not for amusement, to satisfy idle curiosity, or for strictly philosophical inquiry” and that it “[…] cannot construe the experimental use rule so broadly as to allow a violation of the patent laws in the guise of “scientific inquiry,” when that inquiry has definite, cognizable, and not insubstantial commercial purposes.” As regards to Bolar’s argument that public policy favors generic drugs and thus mandates the creation of a new exception in order to allow drug testing required for the regulatory approval, the court stated that it was not a proper forum to debate the issue and that it would not engage in legislative activity proper only for the Congress.

For example, it has been estimated that procedures for marketing authorization for generic products would delay their commercialization by 2-3 years or more in countries with generic pharmaceutical manufacturing capability. See, e.g., Jayashree Watal “Bolar exception to patent rights: Some Economic Implications” SCP Seminar on Exceptions and Limitations to the Rights, 03.11.14, available at: http://www.wipo.int/edocs/mdocs/scp/en/scp_21/scp_21_ref_watal.pdf.

For further information on which products are covered by the exception in various countries, see section “National and Regional Implementation” in this paper.

Roche Products v Bolar Pharmaceutical Co., 733 F.2d. 858 (Fed. Cir. 1984).
Subsequently, the U.S. Congress addressed the lack of any exemption for generic drug testing. The Drug Price Competition and Patent Term Restoration Act (informally known as the Hatch-Waxman Act), introduced an explicit exception to the patent rights, i.e., acts solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use or sale of drugs or veterinary biological products, other than those products primarily manufactured using certain genetic manipulation techniques, were not infringement acts. The general view of the Congress was that it was not appropriate to prevent generic pharmaceutical manufacturers from starting to prepare and obtain regulatory approval for their generic products only after the expiration of the relevant patent, since it would delay the entrance of generic medicines on the market for a substantial period, extending the effective protection period beyond the patent term.

OBJECTIVES AND GOALS

4. The public policy objectives and the goals of the regulatory review exception in many countries aimed at avoiding a de facto extension of the patent term due to a lengthy regulatory approval process, and thus facilitating the marketing of generic medicines immediately after the expiration of the patent term. Consequently, the regulatory review exception is used as a mechanism to encourage competition in the market as soon as patent is expired. As competition almost invariably lowers prices, this exception is considered to promote the affordability of off-patent medicines, and to reduce the cost of treatments and improving access.

5. Thus, in many countries, the policy objective of the exception is to maintain a balance between the interests of the right holders and third parties for the public interest at large. In other words, it is intended to balance the conflicting interests of producers and users of technological knowledge for the mutual benefits of all parties (for example, the pharmaceutical industry which is engaged in research and development and the generic pharmaceutical industry), in a manner that is conducive to social and economic welfare.

6. The use of the regulatory review exception as a mechanism to increase competition has been frequently highlighted by experts and policymakers. Therefore, policymakers in developing countries have been recommended to introduce this exception in their patent laws, among other provisions; Particular attention, however, was given to countries that were actual or potential producers of generics.

---

5 The public policy objectives of the regulatory review exception are discussed in documents SCP/21/3, pages 2 and 3.
6 See the section on the results of implementation of the regulatory review exception in pp. 17 and 18 of this paper.
8 See, e.g., the response of Brazil to the Questionnaire on exceptions and limitations to the rights (hereafter the Questionnaire); Jayashree Watal, "Bolar exception to patent rights: Some Economic Implications" SCP Seminar on Exceptions and Limitations to the Rights, 03.11.14, available at: http://www.wipo.int/edocs/mdocs/scp/en/scp_21/scp_21_ref_watal.pdf.
9 For example, see Carlos M. Correa "The Bolar Exception: Legislative Models and Drafting Options", South Centre, Research Paper 66, March 2016; see also Jayashree Watal, "Bolar exception to patent rights: Some Economic Implications" SCP Seminar on Exceptions and Limitations to the Rights, 03.11.14.
10 Some publications generally recommend countries to use to the full flexibilities contained in the TRIPS Agreement. For example, the WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property urges member states to consider implementing TRIPS flexibilities by incorporating them into their national laws (Element 5.2a).
The third amendment of Israel Patent Law (1998) created a new regime in patent protection of medicines, in order to “balance the conflicting interests of the generic pharmaceutical industry on the one hand and those of the pharmaceutical industry which is engaged in research and development on the other hand” (the explanatory memorandum to the third patent law amendment). According to the Jerusalem District Court Decision,\(^\text{11}\) the public interest in the activities of generic companies combines the significant contributions in promotion of exports from Israel and providing an employment for large numbers of workers, mostly academics, with the public benefits derived from a competition at the pharmaceutical market and the price reduction as a result of the competition.

In Japan, the Supreme Court, in decision concerning generic drugs,\(^\text{12}\) recognized that: (i) if any clinical investigations needed for getting approval of manufacturing generic drugs were not able to be conducted during the time when the patent rights are effective, this would substantially result in third parties not being freely able to use the patented inventions for a considerable length of time, even after the patent rights have expired; and (ii) patent right holders can ensure their economic benefits based on the exclusive licensing of their patented inventions.

### THE REGULATORY REVIEW EXCEPTION AND MULTILATERAL AGREEMENTS

7. The regulatory review exception contained in the Patent Act of Canada permitting the generic manufacturers of pharmaceuticals to produce samples of the patented product for use during the regulatory review process, was examined by a WTO Dispute Settlement Panel in *Canada - Patent Protection of Pharmaceutical Products* case\(^\text{13}\). Specifically, the dispute concerned the regulatory review provision (Section 55.2(1)) and the stockpiling provision (Section 55.2(2)) of the Patent Act of Canada that allowed generic drug manufacturers to override, in certain situations, the rights conferred on the patent owner.

8. The Panel examined whether the above provisions were justified, *inter alia*, under Article 30 of the TRIPS Agreement. Article 30 allows Members to provide limited exceptions to the exclusive rights conferred by a patent, provided that such exceptions do not unreasonably conflict with a normal exploitation of the patent and do not unreasonably prejudice the legitimate interests of the patent owner, taking account of the legitimate interests of third parties. According to Article 30, exceptions to patent rights shall meet three conditions, namely, (i) the exceptions to the exclusive rights must be "limited"; (ii) the exceptions do not unreasonably conflict with a normal exploitation of the patent; and (iii) the exceptions do not unreasonably prejudice the legitimate interests of the patent owner, taking account of the legitimate interests of third parties.

9. The Panel held that Canada's regulatory review provision was justified under Article 30 by meeting all these three cumulative criteria. Specifically, in the Panel's view, this exception was "limited" for the following reasons:

"[...] because of the narrow scope of its curtailment of Article 28.1 rights. As long as the exception is confined to conduct needed to comply with the requirements of the regulatory approval process, the extent of the acts unauthorized by the right holder that are


\(^{12}\) Second Petty Bench of the Supreme Court, April 16, 1999 (Case No.153(ju) of 1998) (Minshu 53 (4) 627).

\(^{13}\) WTO document WT/DS114/R.
permitted by it will be small and narrowly bounded. Even though regulatory approval processes may require substantial amounts of test production to demonstrate reliable manufacturing, the patent owner’s rights themselves are not impeded any further by the size of such production runs, as long as they are solely for regulatory purposes and no commercial use is made of resulting final products [...]".\textsuperscript{14}

10. As regards the second condition of Article 30 which prohibits exceptions that "unreasonably conflict with a normal exploitation of the patent", the Panel considered that:

"[...] Canada was on firmer ground, however, in arguing that the additional period of de facto market exclusivity created by using patent rights to preclude submissions for regulatory authorization should not be considered "normal". The additional period of market exclusivity in this situation is not a natural or normal consequence of enforcing patent rights. It is an unintended consequence of the conjunction of the patent laws with product regulatory laws, where the combination of patent rights with the time demands of the regulatory process gives a greater than normal period of market exclusivity to the enforcement of certain patent rights [...]".\textsuperscript{15}

11. As regards the third condition, the Panel concluded that the exception contained in Section 55 2(1) of the Patent Act of Canada did not prejudice the legitimate interest of the patentee within the meaning of Article 30 of the TRIPS Agreement, subject to the following considerations:

"On balance, the Panel concluded that the interest claimed on behalf of patent owners whose effective period of market exclusivity had been reduced by delays in marketing approval was neither so compelling nor so widely recognized that it could be regarded as a "legitimate interest" within the meaning of Article 30 of the TRIPS Agreement. Notwithstanding the number of governments that had responded positively to that claimed interest by granting compensatory patent term extensions, the issue itself was of relatively recent standing, and the community of governments was obviously still divided over the merits of such claims [...]"\textsuperscript{16}

12. Further, regarding the stockpiling provision contained in Canada’s Patent Act, which allowed producers of generic drugs to make the drugs and begin stockpiling them six months prior to the expiration of the patent, the Panel found that the measure was not justified under Article 30. This was because there were no limitations on the quantity of production for stockpiling which resulted in a substantial curtailment of extended market exclusivity, and, thus, was not "limited" as required by Article 30. Accordingly, the Panel concluded that the stockpiling provision was inconsistent with Article 28.1 as it constituted a "substantial curtailment of the exclusionary rights" granted to patent holders.\textsuperscript{17}

\textsuperscript{14} Paragraph 7.45, page 158, WT/DS114/R.
\textsuperscript{15} Paragraph 7.57, page 161, Ibid.
\textsuperscript{16} Paragraph 7.82, page 168, Ibid.
\textsuperscript{17} Pages 156 and 157, Ibid.
NATIONAL AND REGIONAL IMPLEMENTATION

General experimental/scientific research exception or specific regulatory review exception

13. Laws of many countries provide for the regulatory review exception that was confirmed as being permitted under the TRIPS Agreement in a Canada - Patent Protection of Pharmaceutical Products case. However, countries take different approaches in implementing this exception at the national level.

14. The applicable laws of more than 65 countries have been identified to provide for the exception related to acts for obtaining regulatory approval from authorities. In many countries, there is a specific statutory provision on this exception. For instance, the Intellectual Property Law of Egypt states:

"The following shall not be considered as infringements of that right when carried out by third parties:
[...]
(5) Where a third party proceeds, during the protection period of a product, with its manufacturing, assembly, use or sale, with a view to obtaining a marketing license, provided that the marketing starts after the expiry of such a protection period."

15. In some other countries, the regulatory review exception and experimental/scientific research exception are expressly combined into a single provision. For example, Article 21 of the Patent Law of Jordan states:

"[...]

C. Notwithstanding the provisions of this Law or any other legislation, carrying out research and development, and submitting applications for obtaining approvals to market a product prior to the expiry date of the patent protection shall not be considered an act of civil or criminal infringement."

16. In some other countries, the regulatory review exception is considered as being covered by a provision regarding experimental use or scientific research exception. For example, in Japan, the Supreme Court determined that any clinical investigations of generic drugs, which are performed for the purposes of obtaining the regulatory approval from authorities would be regarded to be "experiments or research" under Article 69(1) of the Japanese patent law. Similarly, in the Russian Federation, while no statutory exception concerning the regulatory review exists, courts have recognized that use of the patented medicine for such purposes is not considered an infringement of rights as it falls within the scope of the provision concerning the research exception.

---

18 See Annex II to this document.
20 See, for example, applicable laws of Argentina, Bosnia and Herzegovina, Croatia, Hungary, Jordan, Portugal, the Republic of Korea, Slovakia and Spain.
21 Article 21 C of Law No. 32 of 1999 on Patents, as last amended by Law No. 28/2007.
22 Second Petty Bench of the Supreme Court, April 16, 1999 (Case No. 153(ju) of 1998) (Minshu 53 (4) 627).
23 Article 1359(2) the Civil Code of the Russian Federation. Specifically, in the Novartis AG case, the Supreme Arbitration Court of the Russian Federation confirmed that manufacturing and submitting drug samples to a scientific examination center for subsequent quality testing, as well as officially registering the drug with the Federal Supervision Service for Healthcare and Social Development (Roszdravnadzor), could not be deemed as an infringement of rights. See document SCP/20/13, p.19.
17. In some other countries, for example in Lithuania and Mexico, the exception is contained not in the law on patents but in the regulations relating to health and/or pharmacy.24

<table>
<thead>
<tr>
<th>Box 3. Classification of source of law</th>
</tr>
</thead>
<tbody>
<tr>
<td>Explicit provision on regulatory review exception in IP or patent legislation</td>
</tr>
<tr>
<td>Regulatory review exception as part of the research or experimental use exception (stated explicitly)</td>
</tr>
<tr>
<td>Regulatory review exception as part of the research or experimental use exception (through case law)</td>
</tr>
<tr>
<td>Explicit provision in other legislations (e.g., relating to health and/or pharmacy)</td>
</tr>
</tbody>
</table>

Users of the exception

18. In many countries, there are no restrictions as to who may use the exception. Specifically, relevant provisions in the laws state that “any person”, “any party”, “any third party” or “any legal person” is entitled to use the exception.25

19. Some other laws refer to the “applicant”, “person” or “enterprise” which requests the marketing authorization.26 In Thailand, the exception is applied to “those who wish to produce, distribute or import the patented pharmaceutical product after the expiration of the patent term”.

---

24 For example, in Mexico, the exception is provided in the Regulations on Health-Related Consumable Goods. In Lithuania, the Law on Pharmacy stipulates this exception to the patent rights.

25 See, for example, Section 119A of the Patents Act 1990 of Australia, Article 73(b) of the Patent Law of Bosnia and Herzegovina, Section 55.2(1) of the Patent Act of Canada; Article 69 of the Patent Law of China; Article 63(2) of the Patent Act of Croatia, Section 3(3)(iv) of the Consolidate Patent Act of Denmark (Act no. 91 of 28 January 2009), Article 30(g) of Law No. 20-00 on Industrial Property of the Dominican Republic, Article 116(e) of the Law on Industrial Property of El Salvador, Article 19(6)(b) of Act XXXIII of 1995 on the protection of Inventions by patents of Hungary and Section 54(2) of the Industrial Property Act 2002 of Kenya.

26 See Article 9(1) of its Federal Law on Patents for Inventions of Switzerland, Article L613-8(d) of its Industrial Property Code of France and Article 69(1)(iv) of its Industrial Property Law of Poland, respectively.
The law in Brazil refers to the “non-authorized third parties […] whose acts aim exclusively producing information […] to obtain regulatory approval”\textsuperscript{27}, whereas in the United States of America “those whose actions are ‘solely for uses reasonably related to the development and submission of information under a Federal Law which regulates the manufacture, use, or sale of drugs or veterinary biological products’” were entitled to use the exception.\textsuperscript{28}

20. The laws of some countries do not expressly state who is entitled to use this exception.\textsuperscript{29}

**Third party supplier in Europe**

21. In Europe, the regulatory review exception is governed by Article 10(6) of the Directive 2001/83/EC (as amended) which states: “Conducting the necessary studies and trials with a view to the application of paragraphs 1, 2, 3 and 4 and the consequential practical requirements shall not be regarded as contrary to patent rights or to supplementary protection certificates for medicinal products.”\textsuperscript{30} National laws in this area vary across the European Union in accordance with how the Directives was implemented in each jurisdiction and in the light of domestic case law. In general, it appears undisputed that a party wishing to carry out trials necessary to obtain marketing authorization for a generic medicine is entitled under the exception to manufacture the required product.\textsuperscript{31} However, there has been some debate over the issue of whether a third party manufacturer which supplies a patent-protected substance to a generic company for its use in tests necessary to obtain marketing authorization should be exempt from patent infringement according to the Directive. The national courts of Poland and Germany were recently called upon to consider this issue in *Astellas Pharma Inc v. Polpharma S.A. Pharmaceutical Works* case, which resulted in the Dusseldorf Court of Appeal referring that question to the Court of Justice of the European Union (CJEU) in 2014.\textsuperscript{32} The CJEU did not issue an interpretation on the subject as the case was later withdrawn.

22. Nevertheless, in some countries, activities of such suppliers are included within the relevant exception. For example, the response to the Questionnaire on exceptions and limitations to patent rights from the United Kingdom in this regard clarified that:

“[…] Section 60(5)(i)(ii) provides that the exception also applies to any other act required for the purpose of such studies, tests and trials. This suggests that manufacturers and suppliers of materials for such studies, tests and trials would also be covered by the exception”.\textsuperscript{33}

\textsuperscript{27} Article 43, Paragraph VII, of Law n. 9.279 of 14 May 1996 (Industrial Property Law) of Brazil.

\textsuperscript{28} Title 35, Section 273(e)(1) of the United States Code.

\textsuperscript{29} See, for example, the responses to the Questionnaire from Costa Rica (on Article 16.2(e) of its Patent Law), Norway (on Section 3(3) No.5 of its Patents Act) and Slovakia (on Article 18(1)(f) of the Patent Act).


\textsuperscript{31} The responses to the Questionnaire from Austria, Germany, Italy, Latvia and Netherlands stated that the manufacturers of pharmaceutical products, especially of generic medicines are entitled to use the relevant exception. See the responses to the Questionnaire provided by Austria (on Section 22 of the Austrian Patent Act), Germany (on Section 11 no. 2b of Patent Act), Italy (on Article 68(1)(b) of the Industrial Property Code), Latvia (on Section 20.3 of the Patent Law of Latvia), and the Netherlands (on Article 53(4) of the Netherlands Patent Act 1995).


\textsuperscript{33} In addition, the exception may be used by anybody seeking to obtain regulatory approval or carrying out health technology assessment for a medicinal product. See the response received by the United Kingdom to the Questionnaire.
23. In Germany, suppliers are only generally exempt, if they are themselves involved in the process for obtaining a marketing authorization, i.e., they are co-organizers of clinical trials.\textsuperscript{34}

Box 4. Astellas Pharma Inc v. Polpharma S.A. Pharmaceutical Works

In 2013, the Polish Supreme Court issued a decision in \textit{Astellas v. Polpharma}\textsuperscript{35}. The Court held that a third party supplier of an active pharmaceutical ingredient (API) to a generic manufacturer infringed the rights of the patent holder, because it had no control of whether the customer used the API for acts related to obtaining a marketing authorization. The Court held that sale of a patented API, irrespective of its purpose, is not covered by the regulatory review exception and therefore constitutes patent infringement.

In the corresponding German proceeding, the Düsseldorf district court held that a third party supplier of API, such as Polpharma, will only be protected by the Bolar exemption when it is a co-organizer of the studies carried out by its customer.\textsuperscript{36} On appeal, the Düsseldorf Court of Appeal felt that some clarification from the Court of Justice of the European Union (CJEU) is required on this issue. In particular, the German court has asked the CJEU whether a third party supplier can be exempt from patent infringement and under what conditions, particularly whether the third party supplier was bound to take measures to ensure the API is only used for the purpose of obtaining regulatory approval.\textsuperscript{37}

**Products covered**

24. In many countries, including Albania, Brazil, Canada, India, South Africa and Viet Nam the exception applies to “any products” that require regulatory approval.\textsuperscript{38}

25. However, in a majority of countries, the coverage of the exception is limited to certain products, such as “pharmaceutical products”\textsuperscript{39}, “human or a veterinary drug or a medical products”\textsuperscript{40}, “patented drugs or patented medical apparatus and instruments”\textsuperscript{41}, “medicines”\textsuperscript{42}, “medicaments”\textsuperscript{43}, “medicinal products”\textsuperscript{44}, “certain medicinal products”\textsuperscript{45}, “pharmaceutical and agricultural chemicals”\textsuperscript{46}, “certain medicinal and plant protection products”\textsuperscript{47}, “allopathic medicines”\textsuperscript{48}, “drugs or veterinary biological products”\textsuperscript{49}, “medicinal products for human use or medicinal products for veterinary use”\textsuperscript{50}, “reference medicine”\textsuperscript{51} and “generic medicines”.\textsuperscript{52}

\textsuperscript{34} See a submission of Germany to the twenty-sevenths session of the SCP to be found at: http://www.wipo.int/scp/en/meetings/session_27/comments_received.html.
\textsuperscript{35} CSK 92/13.
\textsuperscript{36} 4a O 282/10, District Court Düsseldorf, 26/07/2012, to be found at: http://www.paradigma.it/docUpload/docDocumenti/201302514350__Bogni%201.pdf.
\textsuperscript{37} 1-2 U 68/12, Düsseldorf Higher Regional Court order, December 5, 2013, to be found at: https://united-kingdom.taylorwessing.com/fileadmin/files/docs/Polpharma-Astellas_Beschluss_OLG-D%C3%BCsseldorf_ENG.pdf.
\textsuperscript{38} See also the relevant provisions of laws of the Dominican Republic, Hungary, Israel, Italy, Jordan, Malaysia, New Zealand, Pakistan and Portugal.
\textsuperscript{39} Austria, Chile, Costa Rica and Thailand.
\textsuperscript{40} Bosnia and Herzegovina and Croatia.
\textsuperscript{41} China.
\textsuperscript{42} France, Norway and Switzerland.
\textsuperscript{43} Germany.
\textsuperscript{44} Finland, Greece, Lithuania and Poland.
\textsuperscript{45} Denmark, Kenya, Slovakia and Turkey.
\textsuperscript{46} El Salvador and Peru.
\textsuperscript{47} Latvia.
\textsuperscript{48} Mexico. Article 224 of the General Health Law of that country defines allopathic medicines as "[a]ny substance or mixture of substances of natural or synthetic origin, that has a therapeutic, preventive or rehabilitative effect, that is pharmaceutical in form and is identified as such by its pharmacological activity, physical, chemical and biological characteristics, and is registered in the Pharmacopeia of Mexico for allopathic medicines [...]".
26. In Japan, as mentioned above, the exception has been recognized through interpretation of more general exception under Article 69(1) relating to experimentation and research. Since the Supreme Court based its decision on the regulations under the Pharmaceutical Affairs Act, the scope of the decision may be extended to patented inventions for cosmetics, medical equipment, and agricultural chemicals, in addition to certain medicines and agrochemical products.  

27. In the United States of America, in *Eli Lilly and Co. v. Medtronic*, the Supreme Court held that the exception under 35 U.S.C. § 271(e)(1) not only applied to drugs but also to medical devices.  

28. In Australia, the Patents Act 1990 provides that the exception covered the regulatory approval of "pharmaceutical patents" relating to goods that "(i) are intended for therapeutic use; and (ii) are not medical devices, or therapeutic devices" as defined in its applicable law. In addition, the Intellectual Property Laws Amendment (Raising the Bar) Act 2012 introduced another provision providing an infringement exemption for acts for obtaining regulatory approval for non-pharmaceuticals.  

29. In Europe, the European Union (EU) Member States implement Article 10(6) of the Directive 2001/83/EC (as amended), differently, as far as the products covered under the regulatory review exception are concerned. Specifically, while in some European countries, the exception is limited to activities relating to marketing approval of generic medicines, in some other countries, the exception is applied in relation to acts relating to innovative medicines. For example, in the United Kingdom, the exception has been applied in relation to "veterinary medicinal products and medicinal products for human use" which fall within the scope of the Directives 2001/82/EC and 2001/83/EC. On October 1, 2014, Section 60(5)(b) of the Patents Act of the United Kingdom was amended to clarify that the exception also covers innovative products. Similarly, in Norway, the regulatory review exception contained in Section 3(3) No.5 of the Patents Act "applies regardless of whether the test in question relates to generic, further developed, or newly developed medicines."

[Footnote continued from previous page]

43 The United States of America. In addition, Title 35, Section 273(e)(1) of the United States Code clarifies that the exception, as defined in that law, applies to a patented invention "other than a new animal drug or veterinary biological product (as those terms are used in the Federal Food, Drug, and Cosmetic Act and the Act of March 4, 1913) which is primarily manufactured using recombinant DNA, recombinant RNA, hybridoma technology, or other processes involving site-specific genetic manipulation techniques[...]."

44 Netherlands.

45 Sweden.

46 Spain.

47 See submission of Japan in document SCP/23/3, p.5.


49 Section 119A of Patents Act 1990 of Australia.

50 New Section 119B of Patents Act 1990 of Australia reads: "Infringement exemptions: acts for obtaining regulatory approval (non-pharmaceuticals): (1) A person may, without infringing a patent, do an act that would infringe the patent apart from this subsection, if the act is done solely for: (a) purposes connected with obtaining an approval required by a law of the Commonwealth or of a State or Territory to exploit a product, method or process; or (b) purposes connected with obtaining a similar approval under a law of another country or region. [...]". The commentary from Australia stated that "This change effectively expands the pre-existing exemption (which was limited to pharmaceutical inventions) to all technologies; recognizing that technologies other than pharmaceuticals may also suffer delays in bringing products to market as a consequence of lengthy pre-market and pre-manufacturing regulatory approval processes".


Permitted acts

30. Permitted acts in relation to a patented invention under the exception differ among countries. In many countries, acts such as, “studies”, “trials”, “tests”, “examinations” and/or “experiments”, as well as “consequential practical requirements”, “related practical needs” or “related procedures” necessary for obtaining a marketing “authorization”, “permission”, “registration” or “marketing clearance” for a product, as defined in the applicable laws, are permitted under the exception.\(^\text{59}\)

31. For example, in the Netherlands, the permitted acts are the “necessary studies, tests and experiments for demonstrating the equivalence between a generic and reference medical product, the reference medical product being protected by a patent right or SPC”. In Switzerland, the exception applies, inter alia, to “experiments and clinical trials in which a pharmaceutical product containing a protected active ingredient is tested to obtain the data required for marketing approval”.

32. In Germany, studies, experiments and any resulting practical requirements under Section 11 no. 2b of the Patent Act means “any use under the patent’s scope of protection that is intended to meet the prerequisites of a privileged study or a privileged experiment (for example: production or importation of the still protected active substance intended to be used in the experiment)”\(^\text{60}\).

33. In El Salvador, Jordan and Spain “using” the patented invention is a permitted act under the exception.\(^\text{61}\) In Albania, Japan, Poland and Portugal, “making” and “using” the patented invention under the exception are allowed. In Brazil, “making, using; and acts […] regarding patented inventions” which aimed at obtaining regulatory approval, as provided in its law, are permitted acts.

34. In Canada and India, reference was also made to “constructing”\(^\text{62}\) the patented invention, and to a “loan and transfer” in the Republic of Korea. In some other countries, permissible acts included “selling” and “offering for sale” and “import”\(^\text{63}\) and “export”\(^\text{64}\). While exact scope of these activities is subject to interpretation under the relevant national laws, it appears that these fundamentally commercial activities could include, for example, activities of a third party manufacture supplying the active ingredients to a generic company for undertaking tests on such active ingredient to obtain a marketing approval.\(^\text{65}\)

---

\(^\text{59}\) See, for example, Section 22(1) of the Austrian Patent Act, Section 3(3)(iv) of the Consolidate Patents Act of Denmark, Section 3(3)(4) of the Patents Act of Finland, Section 11 no. 2b of Patent Act of Germany, Article 68(1)(b) of the Industrial Property Code of Italy, Section 54(2) of the Industrial Property Act of Kenya and Article 52.1(b) of the Law on Patents of Spain.

\(^\text{60}\) See a response of Germany to the Questionnaire.

\(^\text{61}\) The response to the Questionnaire from Spain explained that “using” refers to “[…] studies and trials and the resulting practical requirements (to obtain authorization of generic medicines), including those providing for use, preparation and obtaining”.

\(^\text{62}\) Section 55.2 (1) of the Patent Act of Canada reads: “It is not an infringement of a patent for any person to make, construct, use or sell the patented invention […].” Section 107A(a) of Patents Act 1970 of India reads: “Certain acts not to be considered as infringement […] any act of making, constructing, using, selling or importing a patented invention […].”

\(^\text{63}\) See, for example, the responses to the Questionnaire from China, Chile, the South Africa, the United Kingdom and Viet Nam.

\(^\text{64}\) See, for example, the responses to the Questionnaire from Chile, Latvia, New Zealand, Pakistan, Peru and the United States of America. See also, the response from Israel which stated that permitted acts under the exception “Any experimental act for obtaining a license to market the product, which may include making, using, import and export”.

\(^\text{65}\) See Astellas Pharma Inc v. Polpharma S.A. Pharmaceutical Works case, above.
35. In addition, in some countries, the requirement of a direct relation between studies, trials and consequential practical requirements, on the one hand, and the permission, authorization or registration by an authority, on the other hand, is noted.\textsuperscript{66}

36. Moreover, the range of covered activities can vary depending on the room for interpretation given in different texts, for example, where expressions such as "acts for regulatory approval", "acts solely for uses reasonably related to regulatory approval" or "acts exclusively aiming at regulatory approval" are used.\textsuperscript{67} For example, as regards words "solely for uses reasonably related to the development and submission of information under a Federal law" found in 35 U.S.C. § 271(e)(1), the Supreme Court of the United States held in Merck KGaA v. Integra Lifesciences I, Ltd.\textsuperscript{68} that the exception broadly protects any pre-clinical testing of patented compounds that is reasonably related to the submission of information to a regulatory agency, and not just late-stage safety and efficacy testing in human subjects. Further, in Momenta Pharmaceuticals, v. Amphastar Pharma,\textsuperscript{69} the Federal Circuit held that the fact that testing is carried out to "satisfy the FDA’s requirements" means it falls within the scope of the exception, even though the activity is carried out after approval and the information collected is never submitted to a regulatory agency, provided that the agency requires such testing or the retention of records for possible inspection.

37. In some other countries, the laws do not specify the acts authorized in relation to the exception, stating generally "uses" or "acts" necessary to obtain the marketing approval".\textsuperscript{70}

Box 5. Merck KGaA v. Integra Lifesciences I, Ltd.

In Merck KGaA v. Integra Lifesciences I, Ltd. Case, the United States Supreme Court decided on the range of permissible activities under 35 U.S.C. §271(e)(1), which creates an exemption from patent infringement for use of a patented invention "solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs."

Pharmaceutical companies investigate a great many compounds that do not turn out to have eventual application as medicines. Merck KGaA investigated some compounds patented by Integra Lifesciences but did not proceed with them further as they showed no promise for the indication that they were interested in. Integra filed suit against Merck for patent infringement. The question was whether the Bolar exception only covers activity relating to a compound for which regulatory approval is actually sought, or whether it covers activity relating to any compound for which it could reasonably be believed that regulatory approval could be sought.

The Court held that the exemption extends to preclinical studies of patented compounds that are appropriate for submission to the FDA in the regulatory process. This includes both preclinical data pertaining to the safety of drugs in humans, and preclinical studies related to a drug’s efficacy, mechanism of action, pharmacology, and pharmacokinetics. The Court vacated a decision by the Federal Circuit, which had limited the §271(e)(1) exemption to research activities that supply information for submission to the FDA. The Court opined that the exemption does not categorically inapplicable to either (1) experimentation on drugs that are not ultimately the subject of an FDA submission, or (2) use of patented

\textsuperscript{66} See the responses to the Questionnaire from Austria, Germany and Italy.

\textsuperscript{67} See, for example, Article 43, Paragraph VII, of Law n. 9,279 of 14 May 1996 (Industrial Property Law) of Brazil, Article 69 (1) (iv) of the Industrial Property Law of Poland, Section 119A of the Patents Act 1990 of Australia, Section 55.2(1) of the Patent Act of Canada, Section 107A of Patents Act 1970 of India and Article 69A(1) of Patent Act 57 of 1978 of South Africa.

\textsuperscript{68} Merck KGaA v. Integra Lifesciences I, Ltd, 125 S. Ct. 2372, No. 03-1237 (June 13, 2005).

\textsuperscript{69} Momenta Pharmaceuticals, v. Amphastar Pharma (868 F.3d 1348 (2012)).

\textsuperscript{70} See the responses to the Questionnaire from Croatia, the Dominican Republic, Kenya and Thailand.
compounds in experiments that are not ultimately submitted to the FDA. Nevertheless, the Court stated that the scope of § 271(e)(1) does not include all experimental activity that at some point, however attenuated, may lead to an FDA approval process. It does not cover basic research that is not done with the intent of identifying possible candidates for future FDA approval.

Acts carried out to obtain regulatory approval in other countries

38. In some countries, the exception applies to acts which are carried out for the purpose of obtaining the regulatory approval in those respective countries. In some other countries, activities made for the purpose of obtaining regulatory approval in other countries are also covered under the exception.

39. For example, in India:

"Section 107A. For the purposes of this Act,-
(a) any act of making, constructing, using or selling or importing a patented invention solely for uses reasonably relating to the development and submission of information required under any law for the time being in force, in India, or in a country other than India, that regulates the manufacture, construction, use or sale of any product;
[...]
shall not be considered as an infringement of patent rights." (emphasis added)71

40. Likewise in Brazil:

"43. The provisions of the previous Article do not apply:
[...]
VII- to acts performed by non-authorized third parties, regarding patented inventions, which aim exclusively the production of information, data and test results directed to procure commerce registration, in Brazil or any other country, to allow the exploitation and commercialisation of the patented product, after the termination of the terms provided in article 10." (emphasis added)72

41. Further, in Norway, the relevant acts carried out for the purpose of obtaining a marketing authorization in a "State that is a Contracting Party to the Agreement on the Establishment of the World Trade Organization of April 15, 1994" are permitted.73 In Germany, the relevant provision stipulates that the effect of the patent does not extend to studies, experiments and any related practical requirements that are necessary to obtain either marketing authorization for medicinal products "within the Member States of the European Union or in third countries".74,75

42. Some laws allowing exportation of patented inventions for the purpose of obtaining marketing approval in a foreign country or for the purpose of obtaining marketing approval in their own country, provide other requirements that must be met. In Australia, the provision concerning the regulatory approval of non-pharmaceuticals stipulates that it is not an infringement of a patent if the act is done solely for the purposes connected with obtaining a

---

71 Section 107A(a) of the Patent Act of 1970 of India.
72 Article 43 (VII) of the Industrial Property Law No. 9.279 of 14/05/1996 as last amended by Law No. 10.196 of 14/02/2001.
73 Section 3(3) No.5 of the Patents Act of Norway.
74 Section 11(2b) of the Patent Act of Germany.
75 Similarly, the applicable laws of Canada, Italy, Israel, Lithuania, the Philippines and Spain expressly cover under the scope of the relevant exception, activities made for the purpose of obtaining regulatory approval in other countries.
similar approval under the law of "another country or region", whereas a provision concerning the pharmaceutical patent allows the exploitation of such patented invention solely for the purposes connected with obtaining a similar regulatory approval under the law of a "foreign country or of a part of a foreign country". However, the provision concerning the pharmaceutical patent "[...] does not apply unless the term of the patent has been extended under Part 3 of Chapter 6 and the goods consist of or contain [...] certain products."

43. In Switzerland, the relevant provision states "The scope of protection conferred by the patent shall not extend to [...] acts necessary to obtain marketing approval for a pharmaceutical product in Switzerland or in countries with comparable regulation for pharmaceutical products." (emphasis added).

Further, the applicable laws of El Salvador, Oman and Peru, while allowing the exportation of the product outside the national territories, state that such exportation shall be permitted only to satisfy the requirements for marketing approval in their respective countries. In addition, the relevant provision in the law of Israel states that it is not an exploitation of the invention if, inter alia, "the effort to obtain a license is made in order to obtain a license in Israel or in a country, in which an experimental act on a patent protected invention for the purpose of obtaining a license is permitted before the patent lapses" (emphasis added).

**Time to file a regulatory review request**

44. In most countries, the use of the patented invention for the purpose of obtaining the regulatory approval from the competent authorities can take place anytime during the term of patent protection. Normally, competitors would start testing and research within a reasonable period before the expiration of the patent.

45. However, the laws of Mexico and Paraguay provided a specific timeframe within which the use shall take place to be covered by the exception. Specifically, Article 167bis, of the Regulations on Health-Related Consumable Goods of Mexico states that "[...] the registration of a generic medicine may be requested, the active substance or ingredient of which is protected by a patent, in order to carry out the corresponding studies, tests and experimental production, within the three years prior to expiry of the patent. In this case, health registration shall be granted only when the validity of the patent ends." (emphasis added).

46. Likewise, Article 34 (d) of Law on Patents for Inventions of Paraguay states that the use of the invention within thirty days before the expiration of the patent term to gather information required for the approval of the product by the competent authority is not an infringement.

---

76 Section 119B of the Patents Act 1990 of Australia.
78 These products are "(a) a pharmaceutical substance per se that is in substance disclosed in the complete specification of the patent and in substance falls within the scope of the claim or claims of that specification; or (b) a pharmaceutical substance when produced by a process that involves the use of recombinant DNA technology, that is in substance disclosed in the complete specification of the patent and in substance falls within the scope of the claim or claims of that specification". See Part 3 of Chapter 6 of Patent Act 1990 of Australia.
79 Article 9(1) of the Federal Law on Patents for Inventions of Switzerland.
80 Article 115 (e) of Law on the Promotion and Protection of Intellectual Property Rights of El Salvador, Section 11(4)(a) of the Industrial Property Rights and their Enforcement for the Sultanate of Oman (Royal Decree No. 67/2008), and Article 39 of Legislative Decree 1075 of Peru.
81 For the purposes of this section, "license" means a certification, permit or any other document required under the law in order to market the product. See Article 54A of the Israel Patent Law 5727-1967.
82 Article 167bis of the Regulations on Health-Related Consumable Goods of Mexico.
83 Article 34 (d) of Law No. 1,630 / 2000 on Patents for Inventions, as last amended by Law No. 2,593 / 2005.
Conditions for the exception to be applied

47. Laws of some countries stipulate some conditions to be met for the exception to apply. For example, in Lithuania, the performance of acts, as provided in the Law on Pharmacy, for the purposes of submitting an application for marketing authorization [...] "shall be without prejudice to the rights granted by the medicinal product patent or by a supplementary protection certificate provided for in the Patent Law of the Republic of Lithuania and in other legal acts regulating the protection of industrial property". In Poland, grant of the marketing authorization "shall be without prejudice to civil liability for putting on the market of a product without the patent holder's consent, where such consent is required". In Costa Rica and the Dominican Republic, the relevant exceptions would apply, provided the actions do not unjustifiably harm the normal working of the patent or cause undue harm to the legitimate interests of the patent holder.

CHALLENGES FACED BY MEMBER STATES IN IMPLEMENTATING THE EXCEPTION

48. As regards the implementation of the regulatory review exception at the national level, in general, two types of challenges have been recognized by some Member States. The first type of challenge relates to the uncertainty about the scope of the regulatory review exception in the national laws. For example, when implementing Article 10(6) of Directive 2004/27/EC in the Netherlands, it is observed that the precise scope of "trials and studies" as well as "consequential practical requirements" referred to in that Article was unclear, in the absence of jurisprudence set by the European Court of Justice. In Turkey, it was reported that the courts pronounced conflicting opinions as regards the scope of the relevant exception. Similarly, the court decisions are not unanimous on this issue in Portugal.

49. The second type of challenge is lack of awareness about this exception among potential users who might benefit from it. For example, the UNCTAD Secretariat reported that even in countries that have enacted the regulatory review exception, it is not necessarily used by generic companies due to lack of their awareness of patent issues, among others.

50. In addition, even if the national law perfectly implements the regulatory review exception, there are other issues that might affect the use of the regulatory review exception by its nationals. For example, absence of production capacity of generic medicines in the territory or the delay in processing applications for regulatory approval by the regulatory authorities were

---

85 Article 16.2(e) of the Patent Law of Costa Rica and Article 30(g) of Law No. 20-00 on Industrial Property of the Dominican Republic.
86 See the response to the Questionnaire from the Netherlands. See also response from Spain which referred to the amendment of the relevant provision of its national law implementing Directive 2004/27/EC and introducing the exception, questioned whether it had a retroactive effect or not. See document SCP/21/3.
87 See submission of Turkey to the SCP 27 to be found at: http://www.wipo.int/scp/en/meetings/session_27/comments_received.html.
88 See a response from Portugal to the Questionnaire and document SCP/21/3, p.9.
89 See submission by UNCTAD in document SCP/25/3, p. 2.
90 Ibid, p. 2. This point was also raised by the TWN with respect to use of exceptions and limitations in general. See document SCP/25/3, paragraph 6. The said document also contains, in paragraph 27, the following observation by TWN: "[...] a lack of technological capacities, especially manufacturing capability, prevents many WIPO Member States from using exceptions and limitations to patent rights. For instance, the vast majority of the developing countries and all LDCs, except Bangladesh, lack the manufacturing capacity in the pharmaceutical sector." In addition, as regards the challenges, the submission from the Russian Federation stated in general that the producers of pharmaceuticals in that country face certain constraints and that various government bodies search for solutions. See the submission of the Russian Federation to the twenty-sevenths session of the SCP.
reported to be relevant to the intended outcome of the regulatory review exception and the issue of access to medicines in general. It is without saying that Member States encounter various challenges when they seek to achieve their intended policy objectives through the implementation of law provisions within its national law. Such general challenges, however, are documented elsewhere and thus are not discussed in this reference document that specifically addresses the issues relating to the regulatory review exception.

RESULTS OF IMPLEMENTATION OF THE EXCEPTION

51. In general, it is recognized that in the absence of the regulatory review exception, competitive products, such as generic medicines, would not be able to enter the regulated product markets for prolonged periods following patent expiry. Thus, some countries reported that the implementation of the regulatory review exception in the national law has a positive effect on the timely regulatory registration and entry of generic versions of medicines into the market.

52. In the United Kingdom, in conjunction with the amendment of Section 60(5)(b) of the Patents Act that clarified the applicability of the exception to innovative products, the government made an impact assessment of the regulatory review exception. It estimated that the amendment would reduce the cost of undertaking trials in the United Kingdom (for example, by eliminating the cost of freedom-to-operate investigations which would save companies between £3,000 to £135,000 per trial) and would make the UK a more attractive place for companies to undertake research and development.

53. As regards the empirical evidence, several studies have analyzed the effect of generics' entry on the prices of originator products and the cost of related treatments. In general, such studies have found the reduction of prices of brand-name medicines due to competition from generic manufacturers. Similarly, in the WTO dispute Canada - Patent Protection of Pharmaceutical Products, Canada demonstrated that generic versions of innovative medicines traded at a significant discount to the innovative version of the medicine. It stated that on

91 See response from South Africa to the Questionnaire, and document SCP/21/3, p.9.
92 See document SCP/26/5.
93 See, e.g., the submission of Mexico (document SCP/23/3), as well as Turkey's submission to the twenty-seventh session of the SCP.
94 For the details of the decision, see the response to the Questionnaire by the United Kingdom at: http://www.wipo.int/export/sites/www/scp/en/exceptions/submissions/uk_3.pdf.
95 "Experimental use and Bolar exemption" Impact Assessment No. BISO402.
96 See, e.g., Joan Rovira et al., "The Impact of Biosimilars' Entry in the EU Market", stating that "[...] the entry of generics can reduce the drug's price by up to 80% of the originators pre-expiry price", January 2011. Another study focusing on the United States of America finds that, for drugs experiencing initial generic entry in 2011–2012, the market exclusivity period (MEP) was 12.6 years for drugs with sales greater than $100 million (in 2008 dollars) in the year prior to generic entry, 12.9 years overall. After generic entry, the brand rapidly lost sales, with average brand unit share of 16% at 1 year; 11% for new molecular entities with pre-generic entry sales of at least $250 million (in 2008 dollars). See brief report "Recent Trends in Brand-name and Generic Drug Competition", Journal of Medical Economics, 2013, 1-8.
97 Similarly, another study based on the Hatch-Waxman Act, finds that "since the Hatch-Waxman, almost all top-selling drugs not covered by patent face generic competition; whereas pre-Hatch-Waxman, only 35% had generics available. Similarly, today more than 70% of prescriptions are for generics, whereas pre-Hatch-Waxman generic prescriptions numbered 15%. At present, with rapid generic substitution [...] the rate of generic penetration is accelerated, with 80% conversion within 6 to 8 weeks. I see Martha M. Rumore, "The Hatch-Waxman Act—25 Years Later: Keeping the Pharmaceutical Scales Balanced", 2009. However, such studies should be treated cautiously as The Hatch-Waxman Act included a number of provisions aimed at facilitating approval of generic drugs by the Food and Drug Administration (FDA) and encouraging generic entry as well as other provisions, such as the extension of the patent term. Therefore, it is difficult to conclude what the specific attribution of the provision on the regulatory review exception in the Hatch-Waxman Act was on these findings.
average: (i) the first and second generic versions of a previously patented product came on the market at just less than 75 per cent of the innovator's price; (ii) when a third and a fourth generic entered, the average price dropped about 20 percentage points to about 54 per cent of the innovator price; (iii) and when a fifth entered, the average fell another ten percentage points to just under 46 per cent of the innovator's price for the same medicine. At the same time, Canada also explained that "while such discounts suggested substantial savings, the quantum of the savings realized would, of course, depend on the degree of market penetration that the generic products achieved. The quantum of the savings would also vary if the innovator adjusted its prices downward in an effort to retain market share".  

54. Nevertheless, it is to be noted that the above studies are not specifically attributable to the implementation of the regulatory review exception under the relevant laws. The empirical evidence focusing on the specific effect of the regulatory review exception on the behaviors of market players and its consequential economic effect is limited. In general, many policymakers view generic medicine competition as the principal method to contain costs of medicines. Therefore, numerous laws, regulations and legal precedents are employed to regulate the structure and competitive environment of this market. The regulatory review exception is one of those elements which, if optimally designed, can be applied in shaping the competitive environment for both generic and originator products.

[Appendix follows]

---

98 WT/DS114/R, footnote 112. Canada also explained that "while such discounts suggested substantial savings, the quantum of the savings realized would, of course, depend on the degree of market penetration that the generic products achieved. The quantum of the savings would also vary if the innovator adjusted its prices downward in an effort to retain market share".

APPENDIX

COMPILATION OF VARIOUS LEGAL PROVISIONS ON THE EXCEPTION REGARDING ACTS FOR OBTAINING REGULATORY APPROVAL FROM AUTHORITIES
# TABLE OF CONTENTS

ARGENTINA .............................................................................................................. 4
AUSTRALIA ................................................................................................................ 4
AUSTRIA .................................................................................................................... 5
BELGIUM ................................................................................................................... 5
BOLIVIA (PLURINATIONAL STATE OF) ................................................................. 5
BOSNIA AND HERZEGOVINA ............................................................................ 6
BRAZIL ..................................................................................................................... 6
BULGARIA ................................................................................................................ 6
CANADA .................................................................................................................... 6
CHILE ....................................................................................................................... 7
CHINA ....................................................................................................................... 7
COLOMBIA .............................................................................................................. 7
COSTA RICA ........................................................................................................... 8
CROATIA .................................................................................................................. 8
CZECH REPUBLIC ............................................................................................... 8
DENMARK ............................................................................................................... 9
DOMINICAN REPUBLIC ..................................................................................... 9
ECUADOR ............................................................................................................... 9
EGYPT ...................................................................................................................... 9
EL SALVADOR ....................................................................................................... 10
FINLAND ................................................................................................................ 10
FRANCE .................................................................................................................. 11
GERMANY ............................................................................................................. 11
GREECE ................................................................................................................ 11
HUNGARY ............................................................................................................. 11
ICELAND ................................................................................................................ 12
INDIA ....................................................................................................................... 12
IRELAND ............................................................................................................... 12
ISRAEL .................................................................................................................... 14
ITALY ....................................................................................................................... 14
JAPAN ...................................................................................................................... 14
JORDAN ................................................................................................................... 15
KENYA ................................................................................................................... 15
LATVIA .................................................................................................................. 15
MALAYSIA ........................................................................................................... 15
MALTA ................................................................................................................... 16
MEXICO .................................................................................................................. 16
MOROCCO ............................................................................................................. 16
NETHERLANDS ................................................................................................... 16
NEW ZEALAND .................................................................................................... 17
NORWAY ............................................................................................................... 17
OMAN .................................................................................................................... 17
PAKISTAN ............................................................................................................ 18
PARAGUAY ........................................................................................................ 18
PERU ....................................................................................................................... 18
PHILIPPINES .................................................................................................... 19
POLAND ................................................................................................................. 19
PORTUGAL ......................................................................................................... 19
REPUBLIC OF KOREA ....................................................................................... 20
SERBIA .................................................................................................................. 20
SINGAPORE ........................................................................................................ 20
ARGENTINA

Artículo 8º de Ley N⁰ 24.766 de Confidencialidad sobre Información.

8º Cuando se trate de un producto o procedimiento protegido por una patente de invención, cualquier tercero podrá utilizar la invención antes del vencimiento de la patente, con fines experimentales y para reunir la información requerida para la aprobación de un producto o procedimiento por la autoridad competente para su comercialización con posterioridad al vencimiento de la patente.

AUSTRALIA


119A Infringement exemptions : acts for obtaining regulatory approval of pharmaceuticals

(1) The rights of a patentee of a pharmaceutical patent are not infringed by a person exploiting an invention claimed in the patent if the exploitation is solely for:

(a) purposes connected with obtaining the inclusion in the Australian Register of Therapeutic Goods of goods that:

(i) are intended for therapeutic use; and

(ii) are not medical devices, or therapeutic devices, as defined in the Therapeutic Goods Act 1989; or

(b) purposes connected with obtaining similar regulatory approval under a law of a foreign country or of a part of a foreign country.

(2) Subsection (1) does not apply to the export from Australia of goods for purposes described in paragraph (1)(b) unless the term of the patent has been extended under Part 3 of Chapter 6 and the goods consist of or contain:

(a) a pharmaceutical substance per se that is in substance disclosed in the complete specification of the patent and in substance falls within the scope of the claim or claims of that specification; or

(b) a pharmaceutical substance when produced by a process that involves the use of recombinant DNA technology, that is in substance disclosed in the complete specification of the patent and in substance falls within the scope of the claim or claims of that specification.

(3) In this section: pharmaceutical patent means a patent claiming:

(a) a pharmaceutical substance; or

(b) a method, use of product relating to a pharmaceutical substance, including any of the following:

(i) a method for producing a raw material needed to produce the substance;

(ii) a product that is a raw material needed to produce the substance;

(iii) a product that is a pro-drug, metabolite or derivative of the substance.
AUSTRIA


22 (1)

[...]

The effect of the patent shall not extend to studies and trials as well as to the consequential practical requirements, as far as they are necessary to obtain a permission, authorization or registration for putting on the market pharmaceutical products.

BELGIUM


6bis § 1er.

[...]

La réalisation des études, des tests et des essais nécessaires en vue de satisfaire aux conditions et modalités prévues dans les alinéas 1er à 7 et les exigences pratiques qui en résultent, ne sont pas considérées comme contraire aux brevets et aux certificats complémentaires de protection pour les médicaments à usage humain.

[...]

BOLIVIA (PLURINATIONAL STATE OF)

Artículo 53 of Decisión N° 689 de 13 de agosto de 2008, sobre la Adecuación de Determinados Artículos de la Decisión 486 por la que se establece el Régimen Común sobre Propiedad Industrial, para permitir el Desarrollo y Profundización de Derechos de Propiedad Industrial a través de la Normativa Interna de los Países Miembros.

53 Incluir la facultad de usar la materia protegida por una patente con el fin de generar la información necesaria para apoyar la solicitud de aprobación de comercialización de un producto.

(Footnote to the Article: Los Países Miembros entienden esta facultad como la Excepción Bolar que facilita el otorgamiento de registros sanitarios.)
BOSNIA AND HERZEGOVINA

Article 73(b) of Patent Law of 2010.

73 The patent holder's exclusive right shall not apply to:

[...]

(b) acts performed for research and development purposes, and for experiments relating to the subject matter of the protected invention, including the acts necessary for obtaining registration or marketing authorization for the product which is a medicine intended for humans or animals or a medicinal product,

[...]

BRAZIL

Article 43 (VII) of the Industrial Property Law No. 9.279 of 14/05/1996, as last amended by Law No. 10.196 of 14/02/2001.

43 The provisions of the previous Article do not apply:

[...]

VII to acts performed by non-authorized third parties, regarding patented inventions, which aim exclusively the production of information, data and test results directed to procure commerce registration, in Brazil or any other country, to allow the exploitation and commercialisation of the patented product, after the termination of the terms provided in article 10.

BULGARIA

Article 20 (7) of the Law on Patents and Utility Models Registration No. 27/2 of 1993, as last amended by Law no. 59/20 of July 2007.

20 The effect of a patent shall not extend to:

[...]

7. (new, State Gazette No. 64/2006, in force as from 09.11.2006; deleted, State Gazette No.31/2007, in force as from 13 April 2007) conduction of necessary researches and tests for the purpose of filing a marketing authorization request for a generic medical product to be used in the human medicine or a generic medical product to be used in the veterinary medicine, as well as any other act related to subsequent practical requirements in connection with the filing of the request.

CANADA

Section 55.2 (1) of the Patent Act (R.S., 1985, c. P-4).

55.2 (1) It is not an infringement of a patent for any person to make, construct, use or sell the patented invention solely for uses reasonably related to the development and submission of information required under any law of Canada, a province or a country other than Canada that regulates the manufacture, construction, use or sale of any product.
CHILE

Article 49 of Law No. 19.039, as last amended by Law No. 20.160.

49

[...]

The patent shall not confer the right to prevent third parties from importing, exporting, manufacturing or producing the subject matter protected by a patent for the purpose of obtaining the registration or health authorization for a pharmaceutical product. The above shall not entitle those products to be marketed without the authorization of the patent owner.

CHINA


Article 69 None of the following shall be deemed an infringement of the patent right:

[...]

(5) any person who produces, uses, or imports patented drugs or patented medical apparatus and instruments, for the purpose of providing information required for administrative examination and approval, or any third party who imports patented drugs or patented medical apparatus and instruments especially for that person.

COLOMBIA

Artículo 53 de Decisión N° 689 de 13 de agosto de 2008, sobre la Adecuación de Determinados Artículos de la Decisión 486 por la que se establece el Régimen Común sobre Propiedad Industrial, para permitir el Desarrollo y Profundización de Derechos de Propiedad Industrial a través de la Normativa Interna de los Países Miembros.

53 Incluir la facultad de usar la materia protegida por una patente con el fin de generar la información necesaria para apoyar la solicitud de aprobación de comercialización de un producto.

(Footnote to the Article: Los Países Miembros entienden esta facultad como la Excepción Bolar que facilita el otorgamiento de registros sanitarios.)

Artículo 3° de Decreto 729 de 2012.

3° Excepción al derecho conferido por la patente. Además de los actos previstos en el artículo 53 de la Decisión Andina 486, el titular no podrá ejercer el derecho que le confiere la patente, respecto de los actos realizados con el fin de generar la información necesaria para presentar una solicitud de aprobación requerida, para que un producto entre al mercado una vez expire la patente. En tal sentido, los terceros estarán facultados para fabricar, utilizar, vender, ofrecer en venta o importar cualquier objeto de la invención patentada exclusivamente para el fin antes mencionado.

Parágrafo. Si un producto es fabricado, utilizado, vendido, ofrecido en venta o importado bajo la excepción del párrafo anterior, sólo podrá ser exportado con el propósito de cumplir los requisitos de aprobación en Colombia.
COSTA RICA


16.2 Provided that the following exceptions do not unjustifiably harm the normal working of the patent, or cause undue harm to the legitimate interests of its owner or its licensee, the rights conferred by the patent shall not extend to:

[...]

(e) the uses necessary to investigate or process or any other requirements to obtain health approval for the purpose of commercializing a product after the patent protecting it expires.

CROATIA

Article 63(2) of the Patent Act No. 173 of 2003, as last amended by Act No. 76/2013.

63 The patent owner’s exclusive right of exploitation of the invention shall not apply to:

[...]

2. acts done for the purposes of research and development and for experiments relating to the subject-matter of the protected invention, including where such acts are necessary for obtaining registration or authorization for putting on the market a product comprising a medicine intended for people or animals, or a medicinal product,

[...]

CZECH REPUBLIC

Section 18(e) of the Patents Act No. 527 of 1990.

18 The rights of the proprietor of the patent shall not be infringed by use of the protected invention:

[...]

(e) in acts relating to the subject-matter of the invention done for experimental purposes including experiments and tests necessary, pursuant to the special legal regulation, before placing a medicine on the market.
DENMARK


3(3) The exclusive right shall not extend to

[...]

(iv) acts delimited to the subject-matter of the patented invention which are necessary for obtaining a marketing authorisation for a medicinal product for humans or animals in the EU, in an EU member state or in other countries or

[...]

DOMINICAN REPUBLIC

Article 30(g) of the Law on Industrial Property No. 20-00 of 18/04/2000, as amended by Law No. 424-06 on implementation of the Dominican Republic-Central America-United States Free Trade Agreement (CAFTA-DR).

30 A patent shall not confer the right to prevent

[...]

(g) those uses necessary in order to obtain health approval and to market a product after the expiry of the patent that protects it.

ECUADOR

Artículo 53 of Decisión N° 689 de 13 de agosto de 2008, sobre la Adecuación de Determinados Artículos de la Decisión 486 por la que se establece el Régimen Común sobre Propiedad Industrial, para permitir el Desarrollo y Profundización de Derechos de Propiedad Industrial a través de la Normativa Interna de los Países Miembros.

53 Incluir la facultad de usar la materia protegida por una patente con el fin de generar la información necesaria para apoyar la solicitud de aprobación de comercialización de un producto

(Footnote to the Article: Los Países Miembros entienden esta facultad como la Excepción Bolar que facilita el otorgamiento de registros sanitarios.)

EGYPT


10

[...]

The following shall not be considered as infringements of that right when carried out by third parties:

[...]
(5) Where a third party proceeds, during the protection period of a product, with its manufacturing, assembly, use or sale, with a view to obtaining a marketing license, provided that the marketing starts after the expiry of such a protection period.

[...]

EL SALVADOR

Article 116 (e) of Law on the Promotion and Protection of Intellectual Property Rights (Legislative Decree No. 604 of 15 July 1993), as inserted by Legislative Decree No. 912 of December 14, 2005.

116 The effects of the patent shall not extend

[...]

(e) To the use by a third party of protected materials that are the subject of a valid patent, in order to generate the necessary information to support an application for a health certificate for a pharmaceutical or chemical-agricultural product submitted to the Supreme Council on Public Health or the Ministry of Agriculture and Livestock, an application that may be submitted once the patent protection term has expired; and if the product is exported outside the national territory, this export shall be permitted only to satisfy the requirements for marketing approval in El Salvador.

FINLAND


3 The exclusive right conferred by a patent shall imply, with the exceptions stated below, that no one may exploit an invention, without the proprietor's consent, by:

[...]

(3) offering, putting on the market or using a product obtained by a process protected by the patent or importing or possessing such product for these purposes.

[...]

The exclusive right shall not apply to:

(4) examinations or experiments or measures arising from practical demands which are needed for an application to obtain a marketing authorisation for a medicinal product and which relate to the invention concerning that medicinal product (21.4.2006/295); or

[...]
FRANCE

Article L613-5 (d) of the Intellectual Property Code, Law No. 92-597 of 01/07/1992, as last amended by Law No. 2007-1540.

5(d) The rights conferred by the patent shall not extend to the studies and tests required with a view to obtaining a marketing authorization for a medicine, or also to the acts necessary for them to be carried out or the authorization to be obtained.

GERMANY

Section 11(2b) of the Patent Act, as last amended by Act of April 4, 2016.

11 The effects of a patent shall not extend to:

[ ... ]

2b. studies, experiments and the practical requirements resulting therefrom which are necessary for obtaining authorisation to place medicinal products on the market in the European Union, or which are necessary for obtaining authorisation to place medicinal products on the market in the Member States of the European Union or in third countries;

GREECE


11 (6) The realization of studies and the tests that are required for the application of paragraphs 1, 2, 3 and 4 and the consequential practical requirements are not considered to infringe the rights which are protected by patents patent or supplementary certificates of protection for the medicines.

HUNGARY


19 (6) The exclusive right of exploitation shall not extend to:

[ ... ]

(b) acts done for experimental purposes relating to the subject matter of the invention, including experiments and tests necessary for the marketing authorisation of the product constituting the subject matter of the invention or the product obtained through the process constituting the subject matter of the invention;
ICELAND

Article 3(3) of the Patents Act No. 17/1991, as last amended by Act No. 126/2011.

3

[...]

The following are excepted from the exclusive right:

[...]

3. use of the invention for experiments which relate to the invention itself, [i.e. studies and trials and other related procedures that are necessary to make possible an application for marketing authorization for e.g. a generic medicinal product and an improved pharmaceutical form];

INDIA


107A For the purposes of this Act,

(a) any act of making, constructing, using or selling or importing a patented invention solely for uses reasonably relating to the development and submission of information required under any law for the time being in force, in India, or in a country other than India, that regulates the manufacture, construction, use or sale of any product;

[ ... ]

shall not be considered as an infringement of patent rights.

IRELAND

Section 42(1)(g) and Section 42(1)(h) of the Patents Act 1992, consolidated unofficial version upto 19 May 2017.

42(1) The rights conferred by a patent shall not extend to —

[...]

(g) acts done in relation to the subject matter of the relevant patented invention which consist of

(i) acts done in conducting the necessary studies, tests and trials which are conducted with a view to satisfying the application requirements of paragraphs 1, 2, 3 and 4 of Article 10 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 (as last amended by Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004) for a marketing authorisation in respect of a medicinal product for human use, or

(ii) acts done in conducting the necessary studies, tests and trials which are conducted with a view to satisfying the application requirements of paragraphs 1 to 5 of Article 13 of Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 (as last

(iii) any other act which is required as a consequence of the acts referred to in subparagraph (i) or (ii) for the purposes specified in those subparagraphs, as appropriate.

(h) insofar as paragraph (g) does not apply, acts done in relation to the subject matter of the relevant patented invention which consist of—

(i) acts done in conducting studies, tests, experiments and trials (including clinical trials and field trials) with a view to satisfying the application requirements for a marketing authorisation or similar instrument (howsoever described) that is required by the law of the State or of any other state in order to sell or supply or offer to sell or supply—

 (I) a medicinal product for human use, within the meaning of subsection (2), or

 (II) a veterinary medicinal product, within the meaning of subsection (2),

or

(ii) any other act done which is required as a consequence of the acts referred to in subparagraph (i) for the purposes specified in that subparagraph, as appropriate.

(2) In this section (other than paragraph (g) of subsection (1))—

‘medicinal product for human use’ means—

(a) any substance or combination of substances having or purporting to have properties for treating or preventing disease in human beings,

or

(b) any substance or combination of substances which may be used on or be administered to human beings with a view either to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis;

‘substance’ means any matter of—

(a) human origin (including human blood and human blood products),

(b) animal origin (including micro-organisms, whole animals, parts of organs, animal secretions, toxins, extracts and blood products),

(c) vegetable origin (including micro-organisms, plants, parts of plants, vegetable secretions and extracts), or

(d) chemical origin (including elements, naturally occurring chemical materials and chemical products obtained by chemical change or synthesis);

‘veterinary medicinal product’ means—

(a) any substance or combination of substances having or purporting to have properties for treating or preventing disease in animals, or
(b) any substance or combination of substances which may be used on or be administered to animals with a view either to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.

**ISRAEL**

*Section 54a of the Patents Law 5727-1967.*

54A An experimental act, which is part of an effort to obtain a license to market the product after the patent has lapsed, does not constitute "exploitation of an invention", if the following two conditions are met:

1. the effort to obtain a license is made in order to obtain a license in Israel or in a country, in which an experimental act on a patent protected invention for the purpose of obtaining a license is permitted before the patent lapses;

2. any product produced under the terms of this section is not used - both while the patent is in effect or thereafter - for any purpose other than obtaining a license as aforesaid;

for purposes of this section, "license" - certification, permit or any other document required under Law in order to market the product.

**ITALY**

*Article 68 of the Industrial Property Code, Legislative Decree No. 30 of 10/02/2005.*

68 Limitazioni del diritto di brevetto

1. La facoltà esclusiva attribuita dal diritto di brevetto non si estende, quale che sia l'oggetto dell'invenzione:

b) agli studi e sperimentazioni diretti all'ottenimento, anche in paesi esteri, di un'autorizzazione all'immissione in commercio di un farmaco ed ai conseguenti adempimenti pratici ivi compresi la preparazione e l'utilizzazione delle materie prime farmacologicamente attive a cio' strettamente necessarie;

**JAPAN**


69 (1) A patent right shall not be effective against the working of the patented invention for experimental or research purposes.
JORDAN

Article 21 C of Law No. 32 of 1999 on Patents, as last amended by Law No. 28/2007.

21

[...]

C. Notwithstanding the provisions of this Law or any other legislation, carrying out research and development, and submitting applications for obtaining approvals to market a product prior to the expiry date of the patent protection shall not be considered an act of civil or criminal infringement.

KENYA

Section 54 (2) of the Industrial Property Act No. 3 of 27/07/2001, as last amended by Act No. 11 of 2017.

54 Rights of owner of patent

[...]

(2) The rights conferred on the owner of the patent under this section shall not apply to acts by third parties necessary to obtain approval or registration of a product from the Institute, for the purpose of commercialising the product after expiry of the patent.

LATVIA

Section 20(3) of the Patent Law adopted on 15/02/2007.

20 The exclusive rights resulting from the patent shall not extend to:

[...]

(3) examination of the subject-matter of a patent, as well as to the research of patented or protected with a supplementary protection certificate medicinal products or plant protection means, which is carried out in order to obtain a permission for the placing on the market thereof;

MALAYSIA

Section 37 (1A) of the Patents Act of 1983, as last amended in 2006.

37 Limitation of rights.

[...]

(1A) The rights under the patent shall not extend to acts done to make, use, offer to sell or sell a patented invention solely for uses reasonably related to the development and submission of information to the relevant authority which regulates the manufacture, use or sale of drugs.
MALTA

Article 27(6)(d) of the Patents and Designs Act, Chapter 417, of 01/06/2002, as last amended by Acts IX of 2003 and XVIII of 2005.

27(6) Notwithstanding subarticles (1) and (2), the proprietor of a patent shall have no right to prevent third parties from performing the acts referred to in subarticles (1) and (2)(b) in the following circumstances:

[ ... ]

(d) when an act is done for purposes which can reasonably be related to the development and presentation of information required by the law of Malta or any other country that regulates the production, use or sale of medicinal or phytopharmaceutical products;

MEXICO

Article 167bis of the Reglamento de Insumos para la Salud (Regulations on Health-Related Consumable Goods).

167 bis

[...] Sin perjuicio de lo establecido en los dos párrafos anteriores, se podrá solicitar el registro de un genérico respecto de un medicamento cuya sustancia o ingrediente activo esté protegida por una patente, con el fin de realizar los estudios, pruebas y producción experimental correspondientes, dentro de los tres años anteriores al vencimiento de la patente. En este caso, el registro sanitario se otorgará solamente al concluir la vigencia de la patente.

MOROCCO

Article 55(d) of Loi n° 17-97 relative à la propriété industrielle, telle que modifiée et complétée par les lois n° 31-05 et n° 23-13.

55 Les droits conférés par le brevet ne s’étendent pas:

[ ... ]

d. aux études et essais requis en vue de l’obtention d’une autorisation de mise sur le marché d’un médicament, ainsi qu’aux actes nécessaires à la réalisation de ces études et essais et à l’obtention de l’autorisation;

NETHERLANDS

Section 53 (4) of the Kingdom Act of 15/12/1994, containing rules in respect of patents (the Dutch Patents Act).

53.4 The performance of necessary studies, tests and experiments in connection with the application of Article 10(1) to (4) of Directive 2001/83/EC on the Community Code relating to medicinal products for human use (Official EC Journal L 311) or Article 13(1) to (5) of Directive 2001/82/EC on the Community Code relating to veterinary medicinal products (Official EC Journal L 311) and the ensuing practical requirements shall not be deemed to constitute an infringement of patents relating to medicinal products for human use or medicinal products for veterinary use, respectively.
NEW ZEALAND


145 It is not an infringement of a patent for a person to make, use, import, sell, hire, or otherwise dispose of the invention solely for uses reasonably related to the development and submission of information required under any law (whether in New Zealand or elsewhere) that regulates the manufacture, construction, use, importation, sale, hire, or disposal of any product.

NORWAY

Section 3(3)(5) of the Act No. 9 of 15/12/1967 on patents (The Norwegian Patents Act), as last amended by Act No.80 of 29/06/2007.

3(3)

[...]

The exclusive right shall not include

[...]

(5) Trials, experiments and similar of a patented medicine that are required to obtain a marketing authorisation for a medicine in a state that is a contracting party to the agreement of 15 April 1994 on the establishment of the World Trade Organization (The WTO Agreement).

OMAN


11

[...]

4 The rights under the patent shall not extend

[...]

e. to the acts of making, constructing, using, or selling the patented invention solely for uses reasonably related to the development and submission of information required under any law of Oman or a country other than Oman that regulates the manufacture, construction, use or sale of any product, provided that any product produced under such authority shall not be made, used, or sold in Oman other than for referred purposes, and that the product shall only be exported outside Oman for purposes of meeting marketing approval requirements of Oman.
PAKISTAN

Section 30(5)(e) of the Patents Ordinance, 2000.

30(5) The rights under the patent shall not extend to

[...]

(e) acts, including tests, necessary for the approval of a product for its commercialization after the expiration of the patent;

PARAGUAY

Artículo 34(d) of Ley N° 1.630/2000 de Patentes de Invenciones, modificada por última vez por la Ley N° 2.593/2005.

34 La patente no dará el derecho de impedir:

[ ... ]

(d) la utilización de la invención desde treinta días antes del vencimiento de la patente con fines experimentales y con el objeto de reunir la información requerida para la aprobación de un producto por la autoridad competente, para la comercialización con posterioridad al vencimiento de la patente; y,

PERU

Artículo 53 of Decisión N° 689 de 13 de agosto de 2008, sobre la Adecuación de Determinados Artículos de la Decisión 486 por la que se establece el Régimen Común sobre Propiedad Industrial, para permitir el Desarrollo y Profundización de Derechos de Propiedad Industrial a través de la Normativa Interna de los Países Miembros.

53 Incluir la facultad de usar la materia protegida por una patente con el fin de generar la información necesaria para apoyar la solicitud de aprobación de comercialización de un producto.

(Footnote to the Article: Los Países Miembros entienden esta facultad como la Excepción Bolívar que facilita el otorgamiento de registros sanitarios.)

Article 39 of Resolution approving the Complementary Provisions to Decision 486 of the Andean Community Commission establishing the Common Regime on Industrial Property (Legislative Decree No. 1075 of June 27, 2008).

39 The patent holder shall not exercise the rights conferred by the patent where a third person uses the subject matter protected by the patent in force to generate the necessary information to support the application for approval to market a pharmaceutical product or agricultural chemical.

Any product produced in accordance with the preceding paragraph may be manufactured, used, sold, put up for sale, or imported into national territory for the generation of information for the purposes of meeting the requirements for the approval to market the product once the patent expires. Likewise, the product may be exported only for the purposes of meeting the requirements of the approval for marketing.
PHILIPPINES

Article 72.4 of Intellectual Property Code of the Philippines (Republic Act No. 8293) as amended by Section 7 of the Universally Accessible Cheaper and Quality Medicines Act of 2008 (Republic Act No. 9502).

72 The owner of a patent has no right to prevent third parties from performing, without his authorization, the acts referred to in Section 71 hereof in the following circumstances:

[...]

4. In the case of drugs and medicines, where the act includes testing, using, making or selling the invention including any data related thereto, solely for purposes reasonably related to the development and submission of information and issuance of approvals by government regulatory agencies required under any law of the Philippines or of another country that regulates the manufacture, construction, use or sale of any product

Provided, that, in order to protect the data submitted by the original patent holder from unfair commercial use provided in Article 39.3 of the Agreement on Trade – Related Aspects of Intellectual Property Rights (TRIPS Agreement), the Intellectual Property Office, in consultation with the appropriate government agencies, shall issue the appropriate rules and regulations necessary therein not later than one hundred twenty (120) days after the enactment of this law;

POLAND

Article 69 (1)(iv) and Article 69(5) of the Industrial Property Law of 30/06/2000, as last amended by Act of 29/06/2007.

69 The following shall not be considered acts of infringement of a patent:

[...]

(iv) the exploitation of an invention to a necessary extent, for the purpose of performing the acts as required under the provisions of law for obtaining registration or authorisation, being, due to the intended use thereof, requisite for certain products to be allowed for putting them on the market, in particular those being pharmaceutical products;

PORTUGAL

Article 102(c) of the Industrial Property Code, as last amended by Law No. 46/2011 of June 24, 2011.

102 The rights conferred by a patent do not extend to:

[...]

(c) Acts performed exclusively for trial or experimental purposes, including experiments for the preparation of the administrative processes required for the approval of products by the competent official bodies, though industrial or commercial exploitation of these products may not commence before expiry of the patent protecting them;
REPUBLIC OF KOREA


96(1) The effects of the patent right shall not extend to the following

1. Working of the patented invention for the purpose of research or experiments (including item permission or reporting on medicines under the Pharmaceutical Affairs Act, and research or experiments for registration of agrochemicals under the Agrochemicals Control Act):

[...]

SERBIA

Article 21(2) of the Law on Patents.

21 The exclusive rights of a right holder referred to in Articles 14 and 15 of this Law shall not apply to:

[ ... ]

2) research and development activities relating to the subject matter of a protected invention, including activities that are necessary for obtaining an authorization from the competent authority for placing on the market a product which is a drug intended for use on humans or animals, or a medicinal product or plant protection products defined by the law regulating plant protection products;

SINGAPORE

Section 66(2)(h) of the Patents Act (Chapter 221), as last amended by the Statutes (Miscellaneous Amendments) Act 2014.

66.2 An act which, apart from this subsection, would constitute an infringement of a patent for an invention shall not be so if —

[...]

(h) it consists of the doing of any thing set out in subsection (1) in relation to the subject-matter of the patent to support any application for marketing approval for a pharmaceutical product, provided that any thing produced to support the application is not —

(i) made, used or sold in Singapore; or

(ii) exported outside Singapore,

other than for purposes related to meeting the requirements for marketing approval for that pharmaceutical product;
SLOVAKIA


18 Rights of a patent owner shall not be infringed if an invention is exploited:

[...]

(f) in activity conducted for experimental purposes which shall also be studies, exams necessary for registration proceedings pursuant to a special regulation. (According to footnote 8a this is Act No 140/1998 Coll. on Medicines and Medical Devices)

SLOVENIA

Article 19(b) of the Industrial Property Act (ZIL-1-UPB3), as amended up to December 6, 2013.

19 The rights conferred by a patent within the meaning of Article 18 shall not extend to:

[...]

(b) acts done for research and experimental purposes of any kind relating to the subject matter of the patent irrespective of their final purpose;

SOUTH AFRICA

Section 69A of the Patents Act No. 57 of 1978, as last amended by Act No. 20 of 2005.

69A Acts of non-infringement.

(1) It shall not be an act of infringement of a patent to make, use, exercise, offer to dispose of, dispose of or import the patented invention on a non-commercial scale and solely for the purposes reasonably related to the obtaining, development and submission of information required under any law that regulates the manufacture, production, distribution, use or sale of any product.

(2) It shall not be permitted to possess the patented invention made, used, imported or acquired in terms of subsection (1) for any purpose other than for the obtaining, development or submission of information as contemplated in that subsection.

SPAIN

Artículo 61(1)(c) of Ley N° 24/2015, de 24 de julio, de Patentes.

Artículo 61.1 Los derechos conferidos por la patente no se extienden:

[...]

(c) A la realización de los estudios y ensayos necesarios para obtener la autorización de comercialización de medicamentos en España o fuera de España, y los consiguientes requisitos prácticos, incluida la preparación, obtención y utilización del principio activo para estos fines.
SWEDEN

Article 3(2) 2nd paragraph, 4 p of Patents Act (1967:837).

3 From the exclusive right are excluded the following acts

[...]


[...]

SWITZERLAND

Article 9 (1)(c) of the Patent Law of 25/06/1954, version as on 01/01/2017.

9 Exceptions to effects of the patent

1. In general

The effects of the patent do not extend to:

[...]

(c) acts necessary for obtaining marketing authorisation for a medicinal product in Switzerland or in countries with equivalent medicinal product control;

THAILAND


36

[...]

The preceding paragraph shall not apply to:

[...]

(4) any act concerning an application for drug registration, the applicant intending to produce, distribute or import the patented pharmaceutical product after the expiration of the patent term;
THE FORMER YUGOSLAV REPUBLIC OF MACEDONIA

Article 91(2) of the Law on Industrial Property adopted on 12/02/2009.

91. The right of the patent holder laid down in Article 89 of this Law regarding the exclusive utilisation of the invention shall not relate to:

[...]

(2) undertaking activities for research and development of the subject of the protected invention, in particular

manufacture, use, offer for sale, export or import of the protected invention, including also activities for obtaining approval for placing medications for human and veterinary medicine and products for protection of plants on the market; and

[...]

TUNISIA

Article 47(e) of the Patents Law No. 2000-84 of 24/08/2000.

47. The rights conferred by the patent shall not extend to the following:

[...]

(e) acts necessary for the manufacture of generic drugs, provided that the commercial exploitation of the product of those acts may not be engaged in until the term of patent protection has expired;

TURKEY

Article 85(3) of the Law No. 6769 of December 22, 2016, on Industrial Property.

85

[...]

(3) The following acts are beyond the scope of patent rights:

[...]

Acts for experimental purpose relating to the subject matter of the invention subjected to market approval including the market approval of medicines and the tests and experiments required therefore.
UNITED KINGDOM

Section 60(5)(b) and Section 60 (5) (i) of the Patents Act of 1977, as amended, Unofficial consolidation upto 1 October 2014.

60(5) An act which, apart from this subsection, would constitute an infringement of a patent for an invention shall not do so if -

[...]

(b) it is done for experimental purposes relating to the subject-matter of the invention;

[...]

(i) it consists of –

(i) an act done in conducting a study, test or trial which is necessary for and is conducted with a view to the application of paragraphs 1 to 5 of article 13 of Directive 2001/82/EC or paragraphs 1 to 4 of article 10 of Directive 2001/83/EC, or

(ii) any other act which is required for the purpose of the application of those paragraphs.

[...] 

Section 60(6D)

For the purposes of subsection (5)(b), anything done in or for the purposes of a medicinal product assessment which would otherwise constitute an infringement of a patent for an invention is to be regarded as done for experimental purposes relating to the subject-matter of the invention.

Section 60(6E)

In subsection (6D), “medicinal product assessment” means any testing, course of testing or other activity undertaken with a view to providing data for any of the following purposes—

(a) obtaining or varying an authorisation to sell or supply, or offer to sell or supply, a medicinal product (whether in the United Kingdom or elsewhere);

(b) complying with any regulatory requirement imposed (whether in the United Kingdom or elsewhere) in relation to such an authorisation;

[...]
Section 60(6F)

In subsection (6E) and this subsection—

"medicinal product" means a medicinal product for human use or a veterinary medicinal product;

"medicinal product for human use" has the meaning given by article 1 of Directive 2001/83/EC(2);

"veterinary medicinal product" has the meaning given by article 1 of Directive 2001/82/EC(3).

[...]

UNITED REPUBLIC OF TANZANIA

Section 12(4)(a) of the Zanzibar Industrial Property Act, 2008 (Act No. 4 of 2008).

12(4)(a) The rights under the patent shall not extend

[...]

to an infringement of a patent for any person who make, construct, use or sell the patented invention solely for uses reasonably related to the development and submission of information required under any law of Zanzibar or a country other than Zanzibar that regulates the manufacture, construction, use or sale of any product.

UNITED STATES OF AMERICA

35 USC § 271(e)(1).

§271. Infringement of patent

[...]

(e)(1) It shall not be an act of infringement to make, use, offer to sell, or sell within the United States or import into the United States a patented invention (other than a new animal drug or veterinary biological product (as those terms are used in the Federal Food, Drug, and Cosmetic Act and the Act of March 4, 1913) which is primarily manufactured using recombinant DNA, recombinant RNA, hybridoma technology, or other processes involving site specific genetic manipulation techniques) solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs or veterinary biological products.

URUGUAY

Article 39(D) of the Industrial Property Law No. 17.164 of 02/09/1999.

Artículo 39 El derecho que confiere una patente no alcanzará a los siguientes actos:

[...]

D) Los realizados exclusivamente con fines de experimentación, incluso preparatorios de una futura explotación comercial, realizados dentro del año anterior al vencimiento de la patente.
VIET NAM


125 Right to prevent others from using industrial property objects

[...]

2. Owners of industrial property objects as well as organizations and individuals granted the right to use or the right to manage geographical indications shall not have the right to prevent others from performing the following acts:

a) Using inventions, industrial designs or layout-designs in service of their personal needs or for noncommercial purposes, or for purpose of evaluation, analysis, research, teaching, testing, trial production or information collection for carrying out procedures of application for licenses for production, importation or circulation of products;

[End of Annex and of document]